Sustained virological response predicts fibrosis regression in chronic hepatitis C patients treated with direct acting antivirals-a single tertiary care centre experience

Gunjal, Rajendra; Devadas, Krishnadas; Tadkalkar, Varun

doi:10.1016/s0168-8278(18)31355-2

Cited by 2 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Ogasawara et al [10] used elastography, controlled regression parameters, FIB-4 and APRI in their follow-up study in which 214 patients with CHC were followed up until the 72nd week after treatment, and it was found that there was a significant regression in all parameters, especially in cirrhotic patients, and it was shown that they can be used in the follow-up of fibrosis. In the study of Gunjal et al [11], patients were followed up with transient elastography, APRI and FIB-4 until the 24th week after DEA treatment, and all three measurements were found to be more significant in cirrhotic and advanced fibrosis cases, and all SVR regressed patients. In the same study, it was found that fibrosis indices increased in patients who could not have SVR.…”

Section: Discussionmentioning

confidence: 99%

“…In the study of Gunjal et al . [11], patients were followed up with transient elastography, APRI and FIB-4 until the 24th week after DEA treatment, and all three measurements were found to be more significant in cirrhotic and advanced fibrosis cases, and all SVR regressed patients. In the same study, it was found that fibrosis indices increased in patients who could not have SVR.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Fibrosis scores that can be used in follow-up of after direct-acting antiviral treatment: APRI, FIB-4, King score and GUCI

Tahtasakal

Öncül²,

Sevgi³

et al. 2021

European Journal of Gastroenterology &Amp; Hepatology

View full text Add to dashboard Cite

Introduction Sustained virologic response in the treatment of chronic hepatitis C can be achieved with direct-acting antivirals (DAA) in recent years. Monitoring virologic and histologic response to treatment is essential and noninvasive methods are preferred. In our study, we aimed to determine the regression of fibrosis following DAA treatment with serum fibrosis indices constituting a noninvasive method. Method Patients with chronic hepatitis C to whom DAA treatment is started between January 2016 and January 2018 in our clinic are evaluated retrospectively. The fibrosis scores [fibrosis 4 index (FIB-4), aminotransferase platelet ratio (APRI), Fibro QKing score, age platelet index, Goteburg University Cirrhosis Index (GUCI), aspartate transaminase/alanine transaminase ratio (AAR)] are calculated with routine biochemical and hematologic tests of DAA-treated patients before treatment, at the end of treatment, and in the 12th and 24th weeks of treatment. In total, the course of seven scores calculated at four separate times including baseline was recorded and compared. Results In total 91 patients are included in the study. The average age was 51.16 ± 13.78 and 59.3% (n = 54) of patients were women. According to the baseline FIB-4 values, the patients were grouped as cirrhotic or noncirrhotic, and 11 of them were cirrhotic (12.1%). Statistically significant regression in APRI, FIB-4, GUCI and King scores is seen in all groups regardless of their cirrhotic status, treatment experience or genotype (P < 0.001). Specified scores had a positive, significant correlation with pretreatment biopsy results [area under curve (AUC): 0.800, 0.782, 0.749 and 0.746]. Conclusion: APRI, FIB-4, GUCI and King scores that have a positive correlation with biopsy can also be used for fibrosis recovery follow-up after treatment with DAAs.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%